Pulse Biosciences, Inc. ( NASDAQ: PLSE) Q4 2024 Earnings Conference Call March 27, 2025 4:30 PM ET Philip Trip Taylor - Investor Relations Paul LaViolette - Chief Executive Officer and Co-Chairman of ...

Plus Therapeutics' Q4 2024 earnings reveal progress with REYOBIQ nearing FDA approval & CNSide's 2025 launch. Key hires & funding bolster milestones.

Oragenics, Inc. (NYSE American: OGEN), a biotechnology company focused on developing novel intranasal therapies for brain-related conditions, today ...

Varied approaches to remote patient monitoring are in development to close care gaps between patients and rheumatologists, ...

On track for multiple clinical updates through mid-2026, including further progress from two ongoing clinical programs and initiation of therapeutic dosing of potential new medicine, all based on our ...

If we want to turn these short-term gains into sustainable change, we must fully unleash the potential of methadone-assisted ...

A DNA nanomachine selectively targets skin cancer by detecting microRNA-7, activating phototherapy and releasing chemotherapy ...

With the newly completed OT-101 and IL-2 Phase 1 trial, Oncotelic is poised to begin further combination trials to determine the added efficacy of OT-101, IL-2, and CKIs in solid tumors such as lung ...

Non-drug approaches can help people cope with stress and despair, says an expert. Read more at straitstimes.com.

Trauma can be a life-altering experience that leaves deep emotional, physical, and psychological scars. It can shake an ...

Agency official says nearly 74,500 children may lose access to life-saving therapeutic food unless funds secured - Anadolu ...

This innovative therapeutic method includes animals ... allowing for adjustments based on patient progress and feedback.